We’re proud to be part of a community that leads with science.
When the new coronavirus emerged in China, Fred Hutch scientists — experts in virology, immunology, data science, and epidemiology — began tracking its spread. And when our region became the first known U.S. epicenter of a COVID-19 outbreak, our researchers were the first to detect it — a discovery that mobilized corporate and civic leaders in the Seattle area to band together and act quickly to flatten the curve.
Your belief in science — and your support of our work — makes all this possible. We are grateful, and we're proud to share how your generosity is helping to stop the pandemic.
More than 60 Fred Hutch researchers have launched COVID-19 research projects, jumping at the opportunity to tackle this new challenge — and fulfill the world’s desperate need to control the pandemic. Our scientists are at the forefront of discovery: mapping the virus’s evolution as it spreads, working to understand and reduce transmission, advancing potential treatments and vaccines, advising policymakers on public health strategies, and more. We’re also learning how to keep cancer patients safe in the age of COVID-19.
Thanks to your generous support, we are moving at record speed to track the virus’s spread and understand its prevalence; search for antibodies that target it; lead trials of experimental treatments and vaccines; and more. You've helped fuel activities across the organization. Highlights include:
Your gift makes it possible to test outside-the-box ideas that are not yet ready for foundation or government funding. Donor-funded pilot awards allow scientists to generate the proof of concept they need to attract larger grants — and they are critical to jump-starting the most innovative projects. Thanks to you, the six investigators listed below have received donor-funded COVID-19 pilot awards. We hope to make five additional awards this summer.
Assistant Professor, Clinical Research Division
Dr. Dey’s project is a “fail fast” study of whether it might be possible to target the microbiome to help patients recover more quickly or reduce the virus's chance of spreading through fecal transmission.
Principal Staff Scientist, Vaccine and Infectious Disease Division
Dr. Kublin’s team is studying microbes in the gut and respiratory tract of COVID-19 patients to look for a correlation between patients’ microbiomes and their clinical outcomes.
Associate Professor, Clinical Research Division
Dr. Oehler is testing a broad panel of FDA-approved cancer drugs against COVID-19 to find treatments that could be effective in early-stage infection.
We’ve been amazed and impressed by the inventive ways people are using their unique skills and interests to work fuel COVID-19 research — all while sheltering at home. Here are a few examples: